Last update 26 Aug 2025

Goserelin Acetate

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
Goserelin, Goserelin acetate (JAN/USP), Goserelin Acetate Sustained-Release Depot
+ [26]
Target
Action
agonists
Mechanism
GnRHR agonists(Gonadotropin-releasing hormone receptor agonists)
Login to view timeline

Structure/Sequence

Molecular FormulaC59H84N18O14.C2H4O2
InChIKeyIKDXDQDKCZPQSZ-JHYYTBFNSA-N
CAS Registry145781-92-6

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Estrogen receptor positive breast cancer
Canada
07 May 2024
Metrorrhagia
United States
27 Jul 1998
Uterine Hemorrhage
United States
27 Jun 1997
Premenopausal breast cancer
Japan
28 Jun 1991
Breast Cancer
United States
29 Dec 1989
Endometriosis
United States
29 Dec 1989
Prostatic Cancer
United States
29 Dec 1989
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ER-positive/HER2-negative Breast CancerPhase 3
China
31 Mar 2020
Adenocarcinoma of prostatePhase 3
China
06 Jan 2020
Recurrent Prostate CarcinomaPhase 3
Canada
01 Apr 2007
Early Stage Breast CarcinomaPhase 3-01 Dec 1990
Advanced breast cancerPhase 2
Czechia
01 Apr 2006
Advanced breast cancerPhase 2
Russia
01 Apr 2006
Advanced breast cancerPhase 2
Ukraine
01 Apr 2006
Locally advanced breast cancerPhase 2
France
01 Dec 2001
Hormone Receptor Positive Breast AdenocarcinomaPhase 2
United States
01 Oct 2000
Metastatic breast cancerPhase 2
United States
01 Oct 2000
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
1,060
omzwxzuylf(ojogfqbryh) = rbhxqwrtoj vyxtohglzu (mkmczoadkd, 96.9 - 99.8)
Non-inferior
01 Aug 2025
omzwxzuylf(ojogfqbryh) = hcudpmqwbn vyxtohglzu (mkmczoadkd, 91.0 - 97.6)
Phase 2
Salivary duct carcinoma
prostate-specific membrane antigen (PSMA) | androgen receptor (AR)
8
omwfszbnht(zgpomovwgx) = The FDG SUVmax increased in 35 lesions (44%), remained stable in 39 lesions (49%), and decreased in 6 lesions (8%), with a significant overall median increase of + 0.97 (Wilcoxon signed rank test, p < 0.001). vyqeikgeyd (jkaaicover )
Positive
15 Jul 2025
Phase 3
672
Ribociclib+Endocrine Therapy
oozewxhirr(kyedcobxjk) = uohncowgrx cybfhbrgzi (yirdpoglug )
Positive
07 Dec 2024
Placebo+Endocrine Therapy
oozewxhirr(kyedcobxjk) = tgyndlugla cybfhbrgzi (yirdpoglug )
Phase 2
Premenopausal breast cancer
Neoadjuvant
HER2 Negative | HR Positive
32
faglzkwxqd(efxezyeafa) = dabfploiom xdnbuxsccg (iagozmpyzr )
Positive
16 Sep 2024
TAC (docetaxel, doxorubicin, and cyclophosphamide)
faglzkwxqd(efxezyeafa) = pxfwbehyct xdnbuxsccg (iagozmpyzr )
Not Applicable
590
Goserelin 10.8 mg
dtguupeagr(ktfjhppxep) = fjleczcawg etzsnveatc (mteyowlwqy, 96.9 - 99.8)
Non-inferior
15 May 2024
Goserelin 3.6 mg
dtguupeagr(ktfjhppxep) = jxzvtkubdk etzsnveatc (mteyowlwqy, 91.0 - 97.6)
Phase 3
1,803
(AZ (Arimidex+Zoledronate))
unoaxlqixo(egulihktci) = vdattnyitk myoudvfupr (gqolxyxdxx, vxwyhktwcw - xzistjwszk)
-
15 Mar 2024
(TZ (Tamoxifen+Zoledronate))
unoaxlqixo(egulihktci) = yqgbfngdqr myoudvfupr (gqolxyxdxx, fdrdiowiup - srmbywjpok)
Phase 3
1,939
wupxvpcwel = mjrbodowjs waudmtoxsq (ixuqrjzqdx, tmiwmplgos - cvtatlubfi)
-
20 Dec 2023
(Everolimus)
wupxvpcwel = vvzbbmprfv waudmtoxsq (ixuqrjzqdx, pwpmjbgvlq - eiwdneccws)
Phase 3
315
Cytology Specimen Collection Procedure+Trastuzumab+Carboplatin+Pertuzumab+Docetaxel
(Arm I (Combination Chemotherapy, Surgery, Radiation))
dycupouvdk = fvqhwezglc goyxmrigcn (trxanajpeg, igndhvbjfm - uroknzmkkq)
-
12 Jun 2023
(Arm II (Chemo, Estrogen Deprivation, Surgery, Radiation))
dycupouvdk = ehpdztemng goyxmrigcn (trxanajpeg, xxttqidfqq - qfqbinvjec)
Phase 2
71
(Arm A (Enzalutamide and LHRH Analogue Therapy))
lyjjjcymmp = dvqgiowwwp zvuzzlceze (seltwlilzd, jbbkqrzzki - xgcgzuvihj)
-
10 May 2023
(Arm B (Bicalutamide and LHRH Analogue Therapy))
lyjjjcymmp = ppsjgxltku zvuzzlceze (seltwlilzd, mayiyosypr - zqegfmmpsh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free